RecruitingNot ApplicableNCT07358130

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy in the First-line Anti-Helicobacter Pylori Treatment

Sponsor

Kaohsiung Medical University

Enrollment

552 participants

Start Date

Oct 21, 2025

Study Type

INTERVENTIONAL

Conditions

Helicobacter Pylori Infection

Summary

(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Subjects with Helicobacter pylori infection

Exclusion Criteria6

Subjects with known hypersensitivity to the study drug.
Subjects with a history of gastric surgery.
Subjects with severe liver cirrhosis or uremia.
Subjects with a history of malignancy within the past five years.
Pregnant or breastfeeding women.
Subjects currently receiving treatment with atazanavir sulfate or rilpivirine hydrochloride.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.